Immunohistochemical Evaluation of M30 and M65 in Barrett’s Esophagus and Esophageal Cancer

INTRODUCTION: Although many markers have been studied in esophageal adenocarcinomas, there is no marker currently available for clinical use. This study aimed to investigate the role of apoptosis in Barrett’s esophagus and adenocarcinoma carcinogenesis, determine whether there is a predictive value of apoptotic-necrotic markers M30 and M65, and examine Barrett’s mucosa and cancerous tissue by the immunohistochemical method.
METHODS: Esophageal tissue biopsy with an upper gastrointestinal endoscopy was performed on participants, who were older than 18 years and newly diagnosed. There were 20 with Barrett’s esophagus, 20 esophageal cancer patients and 20 gastroesophageal reflux disease patients as a control group. Among the tissue samples taken, M30 and M65 were stained with immunohistochemical methods. The samples were examined to see whether there was a significant immunohistochemical difference among the groups in terms of M30 and M65 staining.
RESULTS: There was no statistically significant difference among the groups in terms of M30 expression (p = 0.329). When compared to the control and the Barrett’s esophagus groups, M65 positivity was significantly higher in the adenocarcinoma group (p = 0.0001).
DISCUSSION AND CONCLUSION: There was no statistically significant difference in M30 expression among the groups in our study. M65 was found to be significantly high in esophageal adenocarcinoma. This suggests that necrosis is more dominant in the pathogenesis of esophageal adenocarcinoma. M65 can be used as a predictive marker in esophageal adenocarcinoma.

Barrett's Özofagus ve Özofagus Kanserinde M30 ve M65'in Ýmmünohistokimyasal Olarak Deðerlendirilmesi

GÝRÝÞ ve AMAÇ: Özofagus adenokarsinomlarýnda birçok belirteç çalýþýlmýþ olmasýna raðmen, þu anda klinik kullaným için bir belirteç bulunmamaktadýr. Bu çalýþmada apoptozun Barrett's özofagusu ve adenokarsinom karsinogenezindeki rolünü araþtýrmayý, apoptotik-nekrotik belirteçler M30 ve M65'in prediktif deðeri olup olmadýðýný belirlemeyi ve Barrett's mukozasýný ve kanserli dokuyu immünohistokimyasal yöntemle incelemeyi amaçladýk.
YÖNTEM ve GEREÇLER: 18 yaþýndan büyük ve yeni taný almýþ katýlýmcýlara üst gastrointestinal endoskopi ile özofagus doku biyopsisi yapýldý. Kontrol grubu olarak Barrett's özofagusu olan 20, özofagus kanseri hastasý ve 20 gastroözofageal reflü hastalýðý olan hasta vardý. Alýnan doku örneklerinden M30 ve M65 immunohistokimyasal yöntemlerle boyandý. Örnekler, M30 ve M65 boyamasý açýsýndan gruplar arasýnda anlamlý bir immünohistokimyasal farklýlýk olup olmadýðýný görmek için incelendi.
BULGULAR: Gruplar arasýnda M30 ekspresyonu açýsýndan istatistiksel olarak anlamlý fark yoktu (p = 0,329). Kontrol ve Barrett's özofagus gruplarý ile karþýlaþtýrýldýðýnda, adenokarsinom grubunda M65 pozitifliði anlamlý olarak daha yüksekti (p = 0.0001).
TARTIÞMA ve SONUÇ: Çalýþmamýzda gruplar arasýnda M30 ekspresyonunda istatistiksel olarak anlamlý fark yoktu. Özofagus adenokarsinomunda M65 anlamlý olarak yüksek bulundu. Bu, özofagus adenokarsinomunun patogenezinde nekrozun daha baskýn olduðunu göstermektedir. M65, özofagus adenokarsinomunda prediktif bir belirteç olarak kullanýlabilir.